A name that points only at the ovaries leaves the rest of the story untold
For nearly a century, a name shaped how medicine saw a disease — and how 170 million women understood themselves. In May 2026, the Endocrine Society quietly corrected that name, retiring PCOS in favor of PMOS, a designation that acknowledges the metabolic and endocrine complexity long hidden behind a focus on ovarian cysts. The change is small in letters but large in consequence, representing a reckoning with how imprecise language can delay diagnosis, fragment care, and bind suffering to shame.
- A century-old misnomer had quietly narrowed clinical thinking, steering patients toward fertility narratives while obscuring the insulin resistance, metabolic dysfunction, and cardiovascular risks at the condition's core.
- For millions of women, the mismatch between name and reality meant delayed diagnoses, fragmented treatment, and a stigma rooted in reproductive failure rather than the systemic metabolic disease they actually carried.
- Years of global consensus work, anchored in research published in The Lancet, built the case that the old terminology was not merely imprecise — it was actively constraining how clinicians, patients, and researchers approached the condition.
- The Endocrine Society has launched an eight-stage implementation plan running through 2028, but experts warn that professional commitment and community education must move in tandem for the new name to reshape practice, not just paperwork.
- Whether PMOS follows the rapid uptake of MASLD or the slow drift of pre-diabetes remains an open question — but the stakes are clear for the 170 million women whose condition has long been told only half its own story.
On a warm May afternoon in 2026, the Endocrine Society announced that Polycystic Ovarian Syndrome — PCOS — would be renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. One letter changed. The significance of that change, however, ran far deeper than nomenclature.
The old name had always been the problem. By centering attention on ovarian cysts, it obscured the insulin resistance, metabolic dysfunction, and systemic endocrine disruption that define the condition for most of the 170 million women it affects during their reproductive years. Women searching for answers found articles about infertility and pregnancy loss — not about the metabolic disease they actually had. The condition became synonymous with reproductive failure, and reproductive failure became synonymous with shame.
The push to rename emerged from years of international consensus work, documented in The Lancet. Researchers argued that the old terminology actively constrained clinical thinking, patient self-understanding, and the questions researchers chose to ask. The new name reflects what endocrinologists already knew: this is a metabolic and endocrine disorder that affects the ovaries, not a reproductive disorder that happens to affect metabolism.
Indian specialists welcomed the shift. Endocrinologist Usha Sriram noted that the old framing burdened the condition with reproductive stigma, keeping its broader metabolic and cardiovascular consequences invisible. Obstetrician Jaishree Gajaraj observed that misdiagnosis and overdiagnosis were rampant under the old system, and that clearer nomenclature would guide better clinical practice. Pediatric endocrinologist Tejasvi Seshadri emphasized that good practitioners already treated the condition comprehensively — screening for diabetes, insulin resistance, and fatty liver disease — and the new name simply makes that approach explicit.
The Endocrine Society has mapped an eight-stage implementation process through 2028, from academic publication to inclusion in international guidelines. But endocrinologist Jayashree Gopal offered a note of caution: previous efforts to foreground the metabolic dimensions had not reshaped practice, and a century of entrenched terminology would not dissolve overnight. History offers instructive parallels — the renaming of Non-Alcoholic Fatty Liver Disease to MASLD caught on quickly, while other medical renamings have moved slowly. What remains certain is that 170 million women deserve a name that tells the full truth about what is happening in their bodies.
On a warm May afternoon, endocrinologists around the world marked a quiet milestone: the Endocrine Society announced that a condition affecting 170 million women would be renamed. Polycystic Ovarian Syndrome—PCOS—would become Polyendocrine Metabolic Ovarian Syndrome, or PMOS. One letter changed. The celebration seemed outsized until you understood what that single letter represented: a fundamental shift in how medicine understands a disease that has been misnamed for nearly a century.
The old name was the problem. PCOS focused attention on the ovarian cysts—the visible, obvious feature—and in doing so, obscured everything else. It hid the insulin resistance, the metabolic dysfunction, the endocrine disruption, the systemic consequences that ripple through a woman's body across her entire lifetime. Because the name pointed only to the ovaries, diagnosis lagged. Care fragmented. Research narrowed. Women googled their symptoms and found articles about infertility and pregnancy loss, not about the metabolic disease they actually had. The condition became synonymous with reproductive failure, which meant it became synonymous with shame.
The decision to rename emerged from years of global consensus work, documented in The Lancet by researchers including Helena J. Teede. They argued that the old terminology was not merely imprecise—it was actively harmful. It constrained how clinicians thought about the disease, how patients understood themselves, and what questions researchers bothered to ask. The new name reflects what endocrinologists already knew: this is not a reproductive disorder that happens to affect metabolism. It is a metabolic and endocrine disorder that happens to affect the ovaries.
Usha Sriram, an endocrinologist and founder of DIWAS, an organization focused on women's health, called the change "extremely welcome." She noted that the old framing reduced the condition to its most visible feature and burdened it with reproductive stigma. When women searched for information, they encountered narratives about conception and miscarriage. The broader truth—that PMOS shapes metabolic health, cardiovascular risk, and long-term wellbeing—remained invisible. Jaishree Gajaraj, a senior obstetrician and gynecologist, observed that misdiagnosis and overdiagnosis were rampant under the old system, and that the nomenclature shift would clarify clinical practice and guide appropriate treatment.
Tejasvi Seshadri, a pediatric and adolescent endocrinologist at Rainbow Hospitals in Bengaluru, emphasized that the new name signals something crucial: this is not an ovarian disease in isolation. It is a condition that touches general health and wellbeing. Pediatric endocrinologists, she explained, already practice this comprehensive approach. They run hormone panels, screen for diabetes and insulin resistance, check for metabolic dysfunction-associated fatty liver disease. They do not treat every child the same way. They adjust based on what the data shows. The new nomenclature simply makes explicit what good clinical practice already demands.
The Endocrine Society has outlined an eight-stage implementation process stretching to 2028, moving from academic publication through healthcare system integration to inclusion in international guidelines. But implementation depends on professional societies committing to the change, and on simultaneous community education. Jayashree Gopal, an endocrinologist and diabetologist, offered a note of caution. Previous attempts to emphasize the metabolic aspects had failed. The condition had carried the name PCOS for a century. Urban gynecologists, she suggested, already understood the metabolic dimensions. Would a name change actually shift practice?
History offered a parallel. Non-Alcoholic Fatty Liver Disease was recently renamed Metabolic Dysfunction-Associated Steatotic Liver Disease, and that terminology caught on quickly—partly because the old name carried stigma associated with alcohol. Pre-diabetes, meanwhile, had circulated under many names before settling into one that endured. The question now is whether PMOS will follow the path of rapid adoption or slow resistance. What seems certain is that 170 million women deserve a name that tells the truth about what is happening in their bodies—not a name that points only at the ovaries and leaves the rest of the story untold.
Citas Notables
PCOS restricts and reduces it to about cysts and gave it an ovarian-reproductive emphasis. It is not a one-off reproductive abnormality. This is a syndrome that could have a life-long impact on more than just reproductive health.— Usha Sriram, endocrinologist and founder of DIWAS
This reclassification will be useful to let the world know that it is not a condition isolated to the ovaries, but impacting general health and well-being too.— Tejasvi Seshadri, consultant pediatric and adolescent endocrinologist
La Conversación del Hearth Otra perspectiva de la historia
Why does a name matter so much? The disease is the same whether we call it PCOS or PMOS.
The name shapes what doctors look for and what patients believe about themselves. When the name says "ovarian," clinicians stop looking beyond the ovaries. Patients think it's a fertility problem. The metabolic damage stays invisible.
But doctors must know about the metabolic aspects already, right?
Some do, especially in urban centers. But a name constrains thinking. It tells you where to focus. The old name pointed at cysts. It took decades for medicine to understand that cysts were almost incidental to the real disease.
So this is about changing how medicine thinks, not just what it calls things.
Exactly. The name change is the visible part. The real work is rebuilding diagnosis from the ground up—screening for insulin resistance, metabolic dysfunction, endocrine disruption. Treating each woman based on what her body actually shows, not what the name suggests.
What happens to the 170 million women already diagnosed under the old name?
They're still here, still affected. The hope is that as clinicians adopt the new framework, care improves. But awareness has to build simultaneously. Women need to understand that this is not a fertility disorder they happen to have. It's a metabolic disease that affects fertility among many other things.
And if the name change doesn't stick?
Then we've learned something about how medicine changes. A name alone won't shift practice if the underlying incentives and training don't shift with it. The real test comes in 2028, when it's supposed to be integrated into international guidelines.